biologics
-
With $100M ReCept M&A deal, Omnicell enters growing specialty pharmacy space
Specialty drugs represent a growing share of overall pharmaceutical sales, and Omnicell is acquiring specialty pharmacy technologies company ReCept Pharmacy to enter this market. Omnicell is paying $100 million cash to buy ReCept.
-
Biogen and Samsung land FDA approval for biosimilar to blockbuster Roche drug
The FDA has approved the first biosimilar that references the blockbuster Roche drug Lucentis. The Biogen and Samsung BioLogics joint venture that developed the biologic product have approval to treat three eye conditions that lead to vision loss.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
INVEST Precision Medicine Conference Video: Biologics and the Supply Chain Ballet
This panel highlights how different organizations in the biopharma supply chain are addressing the inherent challenges of producing and delivering cell and gene therapies and biologics.
-
Cell, gene therapies are highly personalized, but manufacturing needs to be standardized
Cell and gene therapy companies currently each have their own “cookie recipe” for manufacturing. But to scale, more standardization is needed, experts said.
-
A decade after biosimilars pathway’s creation, FDA issues final interchangeability rules
The rules are still more restrictive than the European Medicines Agency’s, which allow national governments to determine interchangeability. The FDA would require additional testing to demonstrate products can be freely substituted like generic pharmaceuticals.
-
FDA releases ‘Biosimilars Action Plan,’ aiming to accelerate innovation
Agency will create new review tools and other resources to encourage development of biosimilars.
-
Biosimilars will lead to $110B in global healthcare savings by 2020
Biosimilars compete directly with branded biologics that are now going off patent – and in five years, they’ll account for 20 percent of the global pharmaceutical market.
-
Biogen breaks ground on $1.4B Switzerland plant
Building cost estimates for Biogen’s new Switzerland plant are $400 million higher than previously announced – despite the company’s 11 percent reduction in workforce last year.
-
Oncobiologics raising $50M for Avastin, Humira biosimilars
The company is raising $50 million, on top of some $43 million it’s raised this year, according to regulatory filings.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Duchenne Muscular Dystrophy market to shoot up 100-fold in five years
As a whole host of new Duchenne Muscular Dystrophy therapies mature down the regulatory pathway, […]